Most Read
Risk assessment models for venous thromboembolism in ambulatory patients with cancer: A talk with Prof. Gerotziafas
Prof Gerotziafas is a specialist in thrombosis and hemostasis with a particular interest in cancer-associated...
An interview with Grigorios Gerotziafas
ISTH 2018 – Grigorios...
Summary ESMO Clinical Practice Guideline for the management of venous thromboembolism in cancer patients
Venous thromboembolism (VTE) is the second cause of death in people with cancer, after cancer itself. Cancer and VTE...
ISTH 2018 – Anna Falanga
Anna Falanga Chief of the Department of Immunohematology and Transfusion Medicine and the Thrombosis and Hemostasis...
Managing bleeding in cancer: from anticoagulants to artificial intelligence
Our speakers, Mari Thomas and Miren Taberna, shared some recent updates on the management of bleeding in...
Drug-drug interaction prevalence in CAT patients
Drug-drug interactions (DDIs) between anticoagulants (AC) and anticancer therapies present a significant concern in the...
Incidental VTE: to treat or not to treat? – A debate from the 10th ICTHIC
During the 10th ICTHIC, Prof. Marcello di Nisio (University of Chieti, Italy) and Prof. Marc Carrier (Ottawa Hospital...
Real-world CAT patient profile from the RIETE registry
During the ICTHIC webinar, “What is the profile of the real-world CAT patient?”, Dr. Laurent Bertoletti gave a...
The Evolving Landscape of Cerebral Venous Sinus Thrombosis: Emerging Risk Factors and Treatments
Cerebral venous sinus thrombosis (CVST) is a rare yet serious condition, representing an uncommon manifestation of...